The contribution of propolis in the treatment of COVID-19 (SARS-COV-2): integrative review
Keywords:Propolis; Coronavirus; Phytotherapy; Pandemic; Health teaching.
The purpose of this study was to identify in the literature publications on the contribution of propolis in the treatment of COVID-19 (SARS-CoV-2). To this end, an integrative literature review was conducted with articles published from 2020 to 2021, indexed in the CAPES, SciELO, and Google Academic databases using the descriptors: "propolis," "coronavirus," "phytotherapy," and "pandemic. Eight articles were included in the review, of these, two conducted clinical trials with patients suspected or infected by coronavirus and placebo group, where participants who received propolis had reduced symptoms of the disease, as well as hospitalization time. While six studies worked with a computer simulation approach to test the binding affinity of compounds such as terpenes and flavonoids from honey and propolis as inhibitors against the essential enzymes of COVID-19. Of these, the following compounds had the strongest interactions with the target enzymes: p-coumaric acid, ellagic acid, kaempferol, quercetin, glasperin A, broussoflavonol F, rutin, isorhamnetin, caffeic acid phenethyl ester, and octatriacontyl pentafluoropropionate. These are considered effective and promising inhibitors for the treatment against COVID-19. The authors recommend further investigations, including in vivo to evaluate the predicted affinity of the selected compounds. Despite the encouraging results, it can be concluded that when evaluating the outcomes of the articles included in this review, the use of propolis in protocols is not yet recommended, before further clinical studies are performed.
Ang, L., Song, E., Lee, H. W., Lee, M. S. Lee (2020) Herbal Medicine for the Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of clinical medicine, 9 (5), 1583.
Araújo, M. L. V., da Silva, A. C. F. N., Dias, P. H. P., de Souza, D. R., Daltro, D. C. T., & Souza, M. S. P. L. (2021). SOLUÇÃO COMPUTACIONAL DE APOIO À VIGILÂNCIA EPIDEMIOLÓGICA NO ENFRENTAMENTO À PANDEMIA DA COVID-19 NA BAHIA. Revista Baiana de Saúde Pública, 45(Especial_1), 204-217.
Bafna, K., Krug, R. M., & Montelione, G. T. (2020). Structural similarity of SARS-CoV2 Mpro and HCV NS3/4A proteases suggests new approaches for identifying existing drugs useful as COVID-19 therapeutics. ChemRxiv. 10.26434.
da Cruz, F. B., de Freitas Ferreira, J., Silveira, D., & Fonseca-Bazzo, Y. M. (2021). Avaliação da atividade anti-inflamatória de própolis de abelha Apis mellifera: uma revisão. Research, Society and Development, 10(14), e250101421817-e250101421817.
de Queiroz, A. P. M., Rocha, E. L., dos Reis Rocha, L., & Dias, R. M. F. (2021). ATIVIDADE ANTIMICROBIANA DO EXTRATO DE PRÓPOLIS: UMA REVISÃO. Revista Ciência (In) Cena, 1(13).
Feitosa, A. D. N. A., Freires, M. A. L., Sarmento, T. D. A. B., de Brito, L. M., de Alencar Neta, R. L., & Maracajá, P. B. (2020). PRODUTOS APÍCOLAS E SAÚDE HUMANA: UMA REVISÃO INTEGRATIVA: BEE PRODUCTS AND HUMAN HEALTH: AN INTEGRATIVE REVIEW. Brazilian Journal of Production Engineering-BJPE, 34-44.
Fiorini, A. C., Scorza, C. A., de Almeida, A. C. G., Fonseca, M., Finsterer, J., Fonseca, F. L., & Scorza, F. A. (2021). Antiviral activity of brazilian green propolis extract against sars-cov-2 (Severe acute respiratory syndrome-coronavirus 2) infection: Case report and review. Clinics, 76. e2357.
Forte, G. C., Hennemann, M. L., & Dalcin, P. D. T. R. (2018). Controle da asma, função pulmonar, estado nutricional e qualidade de vida relacionada à saúde: diferenças entre homens e mulheres adultos com asma. Jornal brasileiro de pneumologia, 44, 273-278.
Galvão, C. M. (2006). Níveis de evidência. Acta Paulista de Enfermagem [online]. 19 (2), 5.
Gao, Y., Yan, L., Huang, Y., Liu, F., Zhao, Y., & Cao, L. (2020). Structure of the RNA-dependent RNA polymerase from COVID-19 virus. In Science, 368(6492), 779–782.
Gilani, A. H., Mehmood, M. H., Janbaz, K. H., Khan, A. U., & Saeed, S. A. (2008). Ethnopharmacological studies on antispasmodic and antiplatelet activities of Ficus carica. Journal of ethnopharmacology, 119(1), 1-5.
Güler, H. I., Tatar, G., Yildiz, O., Belduz, A. O., & Kolayli, S. (2020). An investigation of ethanolic propolis extracts: Their potential inhibitor properties against ACE-II receptors for COVID-19 treatment by Molecular Docking Study. ScienceOpen Preprints, 10.
H Elwakil, B., Shaaban, M. M., Bekhit, A. A., El-Naggar, M. Y., & Olama, Z. A. (2021). Potential anti-COVID-19 activity of Egyptian propolis using computational modeling. Future Virology, 16(2), 107-116.
Joshipura, K. J., Hu, F. B., Manson, J. E., Stampfer, M. J., Rimm, E. B., Speizer, F. E., ... & Willett, W. C. (2001). The effect of fruit and vegetable intake on risk for coronary heart disease. Annals of internal medicine, 134(12), 1106-1114.
Khayrani, A. C., Irdiani, R., Aditama, R., Pratami, D. K., Lischer, K., Ansari, M. J., ... & Sahlan, M. (2021). Evaluating the potency of Sulawesi propolis compounds as ACE-2 inhibitors through molecular docking for COVID-19 drug discovery preliminary study. Journal of King Saud University-Science, 33(2), 101297.
Khayyal, M. T., El-Ghazaly, M.A., El-Khatib, A. S., Hatem, A. M., De Vries, P. J. F., El-Shafei, S. (2003) A clinical pharmacological study of the potential beneficial effects of a propolis food product as an adjuvant in asthmatic patients. Fundamental & clinical pharmacology, 17(1), 93-102.
Kosari, M., Noureddini, M., Khamechi, S. P., Najafi, A., Ghaderi A., Sehat, M., & Banafshe, H. R. (2021). The effect of propolis plus Hyoscyamus niger L. methanolic extract on clinical symptoms in patients with acute respiratory syndrome suspected to COVID-19: A clinical trial. Phytotherapy Research, 35(7), 4000-4006.
Kris-Etherton, P. M., & Keen, C. L. (2002). Evidence that the antioxidant flavonoids in tea and cocoa are beneficial for cardiovascular health. Current opinion in lipidology, 13(1), 41-49.
Kwon, M. J., Shin, H. M., Perumalsamy, H., Wang, X., & Ahn, Y. J. (2020). Antiviral effects and possible mechanisms of action of constituents from Brazilian propolis and related compounds. Journal of Apicultural Research, 59(4), 413-425.
Maruyama, H., Sumitou, Y., Sakamoto, T., Araki, Y., & Hara, H. (2009). Antihypertensive effects of flavonoids isolated from brazilian green propolis in spontaneously hypertensive rats. Biological and Pharmaceutical Bulletin, 32(7), 1244-1250.
Matoso, L. M. L., & Matoso, M. B. L. (2021). Extrato de Própolis no Combate ao COVID-19: um Relato de Experiência em Nível da Atenção Básica em Saúde. Ensaios e Ciência C Biológicas Agrárias e da Saúde, 25(1), 85-94.
Mendes, K. D. S., Silveira, R. C. D. C. P., & Galvão, C. M. (2008). Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & contexto-enfermagem, 17, 758-764.
Mishima, S., Yoshida, C., Akino, S., & Sakamoto, T. (2005). Antihypertensive effects of Brazilian propolis: identification of caffeoylquinic acids as constituents involved in the hypotension in spontaneously hypertensive rats. Biological and Pharmaceutical Bulletin, 28(10), 1909-1914.
Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., ... & Stewart, L. A. (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews, 4(1), 1-9.
Muhammad, M., Wallerstein, N., Sussman, A. L., Avila, M., Belone, L., & Duran, B. (2015). Reflections on researcher identity and power: The impact of positionality on community based participatory research (CBPR) processes and outcomes. Critical sociology, 41(7-8), 1045-1063.
Nguyen, T. T. H., Woo, H. J., Kang, H. K., Nguyen, V. D., Kim, Y. M., Kim, D. W., ... & Kim, D. (2012). Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris. Biotechnology letters, 34(5), 831-838.
Ophori, E. A., Eriagbonye, B. N., & Ugbodaga, P. (2010). Antimicrobial activity of propolis against Streptococcus mutans. African Journal of Biotechnology, 9(31), 4966-4969.
Pereira, D. S., Freitas, C. I. A., Freitas, M. O., Maracajpa, P., da Silva, J. B. A., da Silva, R. A., & da Silveira, D. C. (2015). Histórico e principal uso da própolis apícola. Embrapa Amazônia Oriental-Artigo em periódico indexado (ALICE).
Refaat, H., Mady, F. M., Sarhan, H. A., Rateb, H. S., & Alaaeldin, E. (2021). Optimization and evaluation of propolis liposomes as a promising therapeutic approach for COVID-19. International journal of pharmaceutics, 592, 120028.
Sahlan, M., Irdiani, R., Flamandita, D., Aditama, R., Alfarraj, S., Ansari, M. J., ... & Lischer, K. (2021). Molecular interaction analysis of Sulawesi propolis compounds with SARS-CoV-2 main protease as preliminary study for COVID-19 drug discovery. Journal of King Saud University-Science, 33(1), 101234.
Shaldam, M. A., Yahya, G., Mohamed, N. H., Abdel-Daim, M. M., & Al Naggar, Y. (2021). In silico screening of potent bioactive compounds from honeybee products against COVID-19 target enzymes. Environmental Science and Pollution Research, 28(30), 40507-40514.
Silva, K. C. M. D. (2018). Os diferentes tipos de própolis e suas indicações: uma revisão da literatura. Dissertação (Mestrado em Ciências Agroindustriais) – Universidade Federal de Campina Grande, Centro de Ciências e Tecnologia Agroalimentar.
Silveira, M. A. D., De Jong, D., Berretta, A. A., dos Santos Galvão, E. B., Ribeiro, J. C., Cerqueira-Silva, T., ... & da Hora Passos, R. (2021). Efficacy of Brazilian green propolis (EPP-AF®) as an adjunct treatment for hospitalized COVID-19 patients: A randomized, controlled clinical trial. Biomedicine & Pharmacotherapy, 138, 111526.
Vavougios, G. D., Zarogiannis, S. G., Krogfelt, K. A., Gourgoulianis, K., Mitsikostas, D. D., & Hadjigeorgiou, G. (2018). Novel candidate genes of the PARK7 interactome as mediators of apoptosis and acetylation in multiple sclerosis: An in silico analysis. Multiple Sclerosis and Related Disorders, 19, 8-14.
Whittemore, R., & Knafl, K. (2005). The integrative review: updated methodology. Journal of advanced nursing, 52(5), 546-553.
How to Cite
Copyright (c) 2022 Mirele Alves Cassimiro; Lívia Maria Nunes Campelo; Igor José Gomes da Silva
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.